For instance, FLT3 mutations in AML promote proliferation through mTOR signaling, whereas BCR-ABL kinase in CML activates the PI3K/Akt/mTOR pathway by binding to the p85 PI3K regulatory subunit [11,12]. Here, PIK3CB is linked to chronic myelogenous leukemia, BCR-ABL1 positive.